Anavex Life Sciences Corp (AVXL)

[anders2211]

Im sorry, I wasn't really clear in my last post. Allow me to rephrase.
One cannot only compare present SOC with A272 if there is an equal playing level field. The equal playing level field consists of three rules in the comparing rules: 1. Optimized Dosing. 2. Equal period of time patients taking the drug. 3. A statistical number of relevant participants.

When the dose is optimized A273 beats Soc
After 2 years taking the drugs, A273 beats Soc by far
The 6 super responders have been of course far less than the many patients in present SOC but in the next trial Im sure will prove A273 is statistically relevant and beat SOC given the present readout of the trial